ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics
RSLSIRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." “Vy
ReShape Lifesciences Signs Exclusive U.S. Distribution Deal With Recon Supply To Expand Access In VA And DoD Healthcare Systems
RSLSReShape Lifesciences Signs U.S. Distribution Agreement With Recon Supply To Distribute ReShape's Cutting-Edge Portfolio Across VA And DoD Healthcare Systems
RSLSReShape Lifesciences Prices $2.6M Public Offering Of 1,054,604 Shares At $2.50 Per Share
RSLSWhy ReShape Lifesciences Stock Is Soaring Today: Key Drivers Behind Weight-Loss Company's Surge
RSLSReShape Lifesciences gains MDR and UKCA certification for all EU and UK devices, meeting strict regulatory standards well before the 2027 deadline.
ReShape Lifesciences Announces EU Medical Device Regulation Certification For Entire European And U.K Product Portfolio
RSLSReShape Lifesciences Entered Into Equity Distribution Agreement Relating To Sale Of Up To $9.7M Of Shares Of Common Stock
RSLSReshape Lifesciences Q1 EPS $18.98 Up From $(135.37) YoY, Sales $1.11M Down From $1.94M YoY
RSLSReShape Lifesciences Files For Mixed Shelf Offering Of Up To $50M
RSLSTrading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
RSLSTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
RSLSReShape Lifesciences Declares 1-For-25 Reverse Stock Split
RSLSReShape Lifesciences To Present Pre-Clinical Data On Proprietary Diabetes Neuromodulation Device At 12Th Annual Minnesota Neuromodulation Symposium
RSLSReShape Lifesciences Announces It Will Present Pre-Clinical Data On Its Proprietary Diabetes Neuromodulation Device in Poster Presentation At 12th Annual Minnesota Neuromodulation Symposium May 2, 2025
RSLSReshape Lifesciences Receives Notice Of Allowance From USPTO For Patent Application Entitled Intragastric Device
RSLSReShape Lifesciences Receives Notice Of Allowance From
USPTO For US Patent Titled 'High-Frequency Low Duty Cycle Patterns for Neural Regulation'
RSLSPenny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US
RSLSReShape Lifesciences will distribute Motion Informatics' FDA-cleared Stimel-03 rehab device in the U.S., targeting stroke and injury recovery markets.
ReShape Lifesciences Agrees with Motion Informatics to Exclusively Import, Distribute AI-Driven Neurorehabilitation Technology to the U.S. Market
RSLSReShape Lifesciences FY24 EPS $(13.83); Revenue $8.01M Down From $8.68M YoY
RSLSReShape Lifesciences Shares Resumed Trade
RSLSReShape Lifesciences Shares Halt On Circuit Breaker To The Upside, Stock Now Up 302.2%
RSLSReShape Lifesciences Resumed Trade
RSLSReShape Lifesciences Shares Resumed Trade Then Again Halted On Circuit Breaker To The Downside, Stock Now Up 227.3%
RSLSReShape Lifesciences Shares Resumed Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 246.7%
RSLSReShape Lifesciences Shares Halted On Circuit Breaker To The Upside, Stock Now Up 199.6%
RSLSReShape Lifesciences Receives Notice Of Allowance For US Patent Related To Its Diabetes Neuromodulation Technology
RSLSReShape Lifesciences Signs Distribution Agreement Liaison Medical For Lap-Band 2.0 FLEX; Terms Not Disclosed
RSLSReShape Lifesciences Announces Pricing Of Upsized $6M Public Offering Of 2,575,107 Units At A Public {rice Of $2.33 Per Unit
RSLSReShape And Vyome Announced All-Stock Merger; ReShape To Be Renamed Vyome Holdings, Listed As HIND On Nasdaq; ReShape Sells Major Assets To Biorad Medisys; No Financial Terms Disclosed
RSLSReshape Lifesciences Inc Files For Offering Of Up To 2.1M Shares Of Common Stock By Selling Stockholder
RSLSReShape Lifesciences Q3 EPS $(3.11) Up From $(59.36) YoY; Revenue $2.292M Up From $2.155M YoY
RSLSReShape Lifesciences Has Received FDA 510(k) Clearance For ReShape Calibration Tubes And Gastric Balloon Suction Catheter
RSLSReshape Lifesciences's Return On Capital Employed Overview
RSLSBenzinga Pro data, Reshape Lifesciences (NASDAQ:RSLS) reported Q2 sales of $2.89 million. Earnings fell to a loss of $9.58 million, resulting in a 16.57% decrease from last quarter.
